Liraglutide (Saxenda/Victoza): the daily GLP-1 before the weeklies

PRPat Rivera· 23 days ago

Research & educational use only. This content is not medical advice. Consult a qualified healthcare professional before using any peptide compound.

With all the attention on the weekly GLP-1 drugs, it is easy to forget liraglutide, the daily injectable that came first. It is FDA approved as Victoza for diabetes and Saxenda for weight management, with the LEADER cardiovascular trial and the SCALE obesity program behind it.

It is solidly Tier 1. The main practical difference people discuss versus the weeklies is the daily injection schedule and a somewhat smaller average weight effect than the newest agents.

2 Replies

DCDr. Sarah Chen researcher· Expert· 22 days ago

The daily injection schedule is the main real-world adherence difference versus the weekly agents, and it likely contributes to the somewhat smaller average effect seen in practice.

BLBea Lindqvist· Senior· 21 days ago

Still a Tier 1 workhorse though, and the LEADER cardiovascular data give it a stronger evidence base than most of the newer options can claim yet.